Osteoporosis from androgen deprivation therapy in prostate cancer treatment.

BACKGROUND

Bone complications from metastatic disease in prostate cancer have been well documented. Osteoporosis from androgen deprivation therapy (ADT) can further impair quality of life in this already susceptible age group.

OBJECTIVE

We aimed to assess the intermediate and long term effects of ADT on bone density and the development of osteoporosis in men with prostatic cancer, and outline some practical assessment, management and treatment options.

DISCUSSION

Osteoporosis, exacerbated by the use of ADT, reduces both the survival and quality of life of men who may otherwise live for many years with their well controlled prostate cancer. Hence, both preventive and treatment options should be explored and tailored to the individual, including lifestyle modifications (exercise, smoking cessation), vitamin D and calcium supplementation, and the use of bisphosphonates.